Dare to think rare
Dr Lucy McKay is Chief Executive of Medics4RareDiseases, a UK registered charity which is driving attitude change towards rare diseases in the medical profession...
Agencies and the ABPI code of practice
Rina Newton shares her top tips for ensuring agencies comply with the ABPI Code of Practice. Agencies are engaged by pharmaceutical companies because the expertise...
Stand up and be proud: Kyowa Kirin and the Pf Awards
Dan Davies shares Kyowa Kirin’s motivation for entering and sponsoring the Pf Awards. What is Kyowa Kirin? Kyowa Kirin is a highly successful and rapidly growing...
A guide to implementing Agile in pharma
Following his article on Agile and its role in addressing pharma’s productivity problems, Neil Osmond shares his guide to implementing Agile in pharma. If you’ve...
Developing product and patient centric services
What are the trends shaping the successful delivery of patient centric services? The pharmaceutical industry is evolving rapidly and as times change, so do the...
Collaboration is the key to innovation in pharma
Enterprise Europe Network explains how collaboration is the key to innovation in pharma and how businesses should collaborate to grow. Successful business in the pharmaceutical...
Back on track – what’s next for ISO IDMP?
A series of delays may have sapped momentum, but it was never in doubt that the European Medicines Agency would deliver ISO IDMP. Now,...
How can the NHS deliver patient centric care?
‘Patient centricity’, the process of designing a service or solution around a patient’s wants, needs and preferences, is a key aspiration for the NHS....
Working together: NHS and pharma in diabetes
Neil MacDonald, Area Healthcare Lead for MSD in North and East Scotland, on the Pf Award-winning real time data-led joint working project involving the Scottish...
Driving patient centricity in patient-facing programmes
How one company created a core proposition which puts the patient first in all the work it does. All companies within the healthcare sector...
Latest articles
Mind the Generation Gap in pharma marketing and market research
Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents anifrolumab results from Phase III TULIP trial
Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Popular articles
NHS Commercial Framework for Medicines consultation published
NHS England has published the NHS Commercial Framework for Medicines for consultation. NHS England has a significant role to play in supporting patient access to...
Mapping NHS change is key to customer engagement
Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
Pf Power List 2019: Who is shaping the pharma & healthcare sector?
The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019. This year has brought a range of developments...
Medopad and Janssen collaborate on novel digital biomarker for Alzheimer’s disease
Medopad has announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...